Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brian Freeman (NPI 1225141609)

Field	Value
Entity Type	Individual
Organization	Brian Freeman
Address	411 Laurel St Ste A300
City	Des Moines
State	IA
ZIP	50314
Taxonomy	Medical Oncology Physician
NPI Enumerated	August 17, 2006

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This profile is heavily Medicare-centric: the provider reports Total Medicare revenue of $1.8M and has no Medicaid billing on file, so the practice operates effectively as a single-payer (Medicare) billing entity rather than a mixed Medicare/Medicaid provider. Analysts should treat Medicaid-related comparisons as inapplicable because there is no in-state Medicaid activity to evaluate for this NPI.

Revenue concentration is extreme within a narrow set of oncology drug codes: the top 3 Medicare codes by revenue account for 68.9% of this provider's total Medicare revenue, driven primarily by J9271 at $799.8K (45.7%), J9144 at $294.1K (16.8%), and J9264 at $112K (6.4%). This concentration indicates that a few high-cost infused agents dominate the payer mix and revenue risk for this practice.

The code mix and top revenue drivers indicate a medical oncology infusion service focused on immunotherapy and monoclonal antibody treatments: J9271 (pembrolizumab), J9144 (daratumumab with hyaluronidase), and J9264 (nab‑paclitaxel) together make up the bulk of revenue, with additional supportive and biologic therapies present (J2506 pegfilgrastim, J0897 denosumab, J1569 immune globulin). The presence of infusion administration codes (96413, 96365, 96367) and G0498 further supports an on-site infusion/clinic model rather than a purely consultative practice.

Competitive standing is mixed by code: for the largest single revenue code J9271 the provider ranks #479 of 1841 (74th percentile) which is characterized as typical, unremarkable volume nationally, while J9264 ranks #28 of 118 (76th percentile) also described as typical. Conversely, the provider’s 99214 E/M volume is a notable outlier—1.1K claims and $93.8K revenue—ranking #10040 of 479517 providers (98th percentile; notably above typical national volume), indicating substantially higher office-visit activity relative to most Medicare clinicians.

Operational footprint signals routine in‑office ancillary services: high-percentile lab and phlebotomy volumes (80053 at 868 claims, ranks in the 93th percentile; 85025 at 1.1K claims, 93th percentile; 36415 at 718 claims, 94th percentile) suggest the practice performs substantial on-site monitoring and draws for therapy patients. These downstream services align with frequent infusion cycles and the need for serial labs in oncology management.

Use of supportive and chronic therapy codes points to a full-spectrum oncology caseload: J2506 pegfilgrastim ($23.1K), J0897 denosumab ($88.6K), and J0881 darbepoetin alfa ($41K) appear regularly in the billing mix, reflecting engagement in marrow-supportive care and bone-health management alongside cytotoxic and immune therapies. This mix increases clinical complexity and payer exposure beyond single-dose infusions.

Market positioning is not that of a national leader for most biologic agents: several high-revenue drugs are described as "typical, unremarkable volume" despite meaningful absolute revenue, and some biosimilar and specialty product ranks are low (Q5115 at $62.7K ranks #63 of 79, 19th percentile; J1569 at $60.5K ranks #438 of 542, 19th percentile), indicating selective or limited use of certain agents compared with peers. Overall, the practice appears to be a mid‑to‑upper‑volume regional oncology infusion provider rather than a top national center for these drugs.

NPI tenure indicates an established practice history: the NPI was enumerated on 2006-08-17 (~20 years ago), which aligns with a long operating window and likely sustained referral relationships and clinic workflows that support the observed infusion-heavy, Medicare-focused revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,600	$40	$799.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$294.1K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	11,200	$10	$112K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,050	$90	$93.8K
J0897	Injection, denosumab, 1 mg	4,920	$20	$88.6K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,790	$40	$62.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,680	$40	$60.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	20,500	$1	$41K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	410	$90	$38.9K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	310	$70	$23.1K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Brian Freeman — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	12	30	17,200	$40	$902.3K
J9144	7	10	9,900	$40	$476.8K
J1569	8	10	2,680	$40	$133.6K
J9264	3	10	13,700	$10	$133.2K
J0897	41	190	1,920	$20	$74.1K
Q5115	5	10	1,790	$30	$71.4K
J0881	6	10	15,520	$1	$43.2K
J2506	11	20	440	$80	$38.9K
96413	16	80	210	$90	$24K
J9217	43	50	140	$130	$23.4K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Brian Freeman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
State University Of Iowa	IA	Dentist	$0	$5.6M

Nearby Providers

Other providers in the same ZIP code as Brian Freeman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
Des Moines Independent Community School District	IA	Local Education Agency (LEA)	$0	$22.8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$14.1M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Mercy Clinics Inc	IA	Pediatric Adolescent Medicine Physician	$0	$10.7M
Des Moines River Physicians, LLC	IA	Emergency Medicine Physician	$0	$8.1M
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.9M
Vita Health Services	IA	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$7.5M

Brian Freeman — Billing Profile & Reimbursement Data

Sign up for Brian Freeman — Billing Profile & Reimbursement Data policy alerts

Brian Freeman — Billing Profile & Reimbursement Data

Sign up for Brian Freeman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References